Real-World Effectiveness and Safety of Ustekinumab for Ulcerative Colitis From 2 Tertiary IBD Centers in the United States.

Simon J HongNoa Krugliak ClevelandShintaro AkiyamaSamantha ZullowYangtian YiSeth R ShafferLisa B MalterJordan E AxelradShannon ChangDavid P HudesmanDavid T Rubin

Published in: Crohn's & colitis 360 (2021)

In this cohort of mostly biologic-refractory UC patients, treatment with ustekinumab achieved remission in nearly half of them at 12 months, and was associated with an overall favorable safety profile. These results are modestly better than the pivotal trials.

Keyphrases

ulcerative colitis
end stage renal disease
ejection fraction
peritoneal dialysis
patient reported outcomes
patient reported